A detailed history of Sphera Funds Management Ltd. transactions in Immatics N.V. stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 721,111 shares of IMTX stock, worth $5.89 Million. This represents 1.51% of its overall portfolio holdings.

Number of Shares
721,111
Previous 731,111 1.37%
Holding current value
$5.89 Million
Previous $8.5 Million 3.15%
% of portfolio
1.51%
Previous 1.24%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.93 - $12.92 $109,300 - $129,200
-10,000 Reduced 1.37%
721,111 $8.23 Million
Q2 2024

Aug 14, 2024

BUY
$9.78 - $13.49 $635,700 - $876,850
65,000 Added 9.76%
731,111 $8.5 Million
Q1 2024

May 15, 2024

BUY
$10.23 - $12.94 $460,350 - $582,300
45,000 Added 7.25%
666,111 $7 Million
Q4 2023

Feb 14, 2024

BUY
$7.36 - $10.89 $28,983 - $42,884
3,938 Added 0.64%
621,111 $6.54 Million
Q2 2023

Aug 14, 2023

SELL
$5.92 - $12.72 $968,979 - $2.08 Million
-163,679 Reduced 20.96%
617,173 $7.12 Million
Q4 2022

Feb 14, 2023

SELL
$8.05 - $11.58 $117,159 - $168,535
-14,554 Reduced 1.83%
780,852 $6.8 Million
Q3 2022

Nov 14, 2022

BUY
$3.31 - $13.06 $214,137 - $844,903
64,694 Added 8.85%
795,406 $7.95 Million
Q2 2022

Aug 15, 2022

BUY
$6.0 - $9.37 $652,722 - $1.02 Million
108,787 Added 17.49%
730,712 $6.37 Million
Q4 2021

Feb 14, 2022

SELL
$10.81 - $14.38 $1.93 Million - $2.56 Million
-178,118 Reduced 22.26%
621,925 $8.36 Million
Q3 2021

Nov 15, 2021

BUY
$11.58 - $15.46 $9.26 Million - $12.4 Million
800,043 New
800,043 $10.4 Million
Q1 2021

May 17, 2021

SELL
$10.24 - $14.6 $8.43 Million - $12 Million
-823,391 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$9.67 - $12.05 $226,190 - $281,861
23,391 Added 2.92%
823,391 $8.88 Million
Q3 2020

Nov 12, 2020

BUY
$8.73 - $15.15 $6.98 Million - $12.1 Million
800,000 New
800,000 $8.49 Million

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $623M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.